Ionis to hold second quarter 2024 financial results webcast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
July 22, 2024 1:06 PM EDTJefferies analyst Akash Tewari raised the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $77.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "IONS released Angelman data this AM - overall we thought the data (albeit early) looks ok/encouraging: 1) IONS582's efficacy... More
Goldman Sachs Reiterates Sell Rating on Ionis Pharmaceuticals (IONS)
July 22, 2024 12:04 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Sell rating and $33.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).
The analyst comments "Ahead of the 2024 Angelman Syndrome Foundation conference, IONS reported six-month Ph1/2 data on antisense oligonucleotide (ASO) ION582 in Angelman syndrome (n=11, 13 and 27 at the low, medium and high doses), where 67% of medium/high-dose patients improved vs. natural history,... More
